Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
CORXEL Pharmaceuticals has raised $287 million in a Series D1 financing to advance its lead obesity program, an oral GLP-1 drug (CX11) that the company has positioned as comparable to injectable weight-loss therapies
Ditzenberger GL et al
When a cardiovascular event occurs in someone taking weight loss medication, it may reflect their pre-existing risk profile rather than a medication effect
Dominguez, often see patients via telehealth
US$ 21.27
US$ 20.47
US$ 22.85
US$ 26.13
US$ 28.88
US$ 28.97
US$ 24.76
US$ 23.08
US$ 29.00
US$ 27.95
